SB756050

Cat. No.:	HY-102016
CAS No.:	447410-57-3
Molecular Formula:	$C_{21}H_{28}N_2O_8S_2$
Molecular Weight:	500.59
Target:	G protein-coupled Bile Acid Receptor 1
Pathway:	GPCR/G Protein
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 150 mg/mL (299.65 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.9976 mL	9.9882 mL	19.9764 mL
5 mM	0.3995 mL	1.9976 mL	3.9953 mL
10 mM	0.1998 mL	0.9988 mL	1.9976 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

SB756050 is a selective TGR5 agonist. SB756050 has the potential for type 2 diabetes treatment.

In Vitro

TGR5 is a bile acid receptor and a potential target for the treatment of type 2 diabetes (T2D)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SB756050 is well‐tolerated; it is readily absorbed, exhibited nonlinear pharmacokinetics with a less than dose‐proportional increase in plasma exposure above 100 mg, and demonstrates no significant changes in exposure when co‐administered with sitagliptin. SB756050 demonstrates highly variable pharmacodynamic effects both within dose groups and between doses, with increases in glucose seen at the two lowest doses and no reduction in glucose seen at the two highest doses. The glucose effects of SB756050 sitagliptin are comparable to those of sitagliptin alone, even though gut hormone plasma profiles are different[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Death Discov. 2020 Jul 6;6:56.
- R Soc Open Sci. 2020 Jul 8;7(7):200635.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Hodge RJ, et al. Safety, Pharmacokinetics, and Pharmacodynamic Effects of a Selective TGR5 Agonist, SB-756050, in Type 2 Diabetes. Clin Pharmacol Drug Dev. 2013 Jul;2(3):213-22.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA